Working… Menu

Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) in Duchenne Muscular Dystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03936894
Recruitment Status : Recruiting
First Posted : May 3, 2019
Last Update Posted : February 24, 2021
Foundation to Eradicate Duchenne
Information provided by (Responsible Party):
Christopher Spurney, Children's National Research Institute

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : April 2022